User's blog

Author: Paramraj Singh Sondhi

  • Trial-Specific Insights

    The Trial-Specific Insights section within the DecenTrialz dashboard provides Sponsors and CROs with a granular view of each clinical trial’s operational performance. Unlike the broader dashboard overview, this view focuses solely on a single study, offering real-time, actionable insights across participant engagement, site responsiveness, protocol alignment, and referral readiness.

    This functionality is essential for identifying trial-specific challenges, validating site activity, and making timely adjustments to recruitment strategies, all while maintaining compliance and data traceability.

    Who Can Access Trial-Specific Insights

    Trial-Specific Insights are visible to:

    • Sponsor Administrators with access to the designated trial
    • CRO Project Leads and Clinical Operations Managers assigned by the Sponsor
    • Compliance and Quality Monitors (view-only access, if granted)

    Access is role-gated, and all views are logged to maintain audit integrity under HIPAA, ICH-GCP, and 21 CFR Part 11 requirements.

    Key Metrics Included in Trial-Specific Insights

    Each insight panel is organized by topic area and updated in real time. The standard views include:

    1. Participant Funnel Performance

    • Number of participants matched to the trial
    • Percentage of matches who completed the pre-screener
    • Pass-through rate based on eligibility criteria
    • Drop-off rate at each pre-screening stage
    • Top reasons for ineligibility (automatically categorized)

    2. Site-Level Activity

    • Site-wise breakdown of participant matches
    • Response times from site coordinators
    • Acceptance vs. rejection rates of applicants
    • Notes or reasons recorded by sites during rejection

    3. Timeline Progression

    • Days since trial launch
    • Days since last participant referral
    • Enrollment velocity vs. projected targets
    • Upcoming milestones or IRB renewal dates

    4. Protocol Consistency Flags

    • Sites using outdated eligibility criteria (flagged automatically)
    • Sites missing required documents (e.g., IRB approval letters)
    • Variance in pre-screener outcomes across regions (which may indicate interpretation gaps)

    Visual Tools and Data Filters

    Trial-Specific Insights include dynamic charts, heat maps, and downloadable tables. Available filters include:

    • By Site
    • By Geography
    • By Eligibility Outcome
    • By Demographics (de-identified)
    • By Time Period (rolling or custom)

    Users can export customized reports in .CSV or .PDF format to share with internal stakeholders, oversight boards, or clinical partners.

    Benefits of Using Trial-Specific Insights

    This module enables Sponsors and CROs to:

    • Proactively adjust recruitment strategy based on real-world performance
    • Identify and address site-level issues such as low responsiveness or unclear communications
    • Validate consistency in participant qualification across sites
    • Ensure compliance readiness through real-time documentation visibility
    • Support IRB communications with transparent eligibility and enrollment records

    Key Note: Trial-Specific Insights are not merely passive data views, they are decision-making tools that empower sponsors and CROs to steer their studies with precision. With real-time visibility into each site’s performance and participant journey, you can address emerging issues early, optimize outreach, and uphold your regulatory obligations with confidence.

  • Dashboard Overview

    The dashboard is the centralized command center for Sponsors and CROs managing clinical trials on the DecenTrialz platform. It provides a secure, real-time overview of key performance indicators (KPIs), participant activity, site-level metrics, and protocol compliance, enabling data-informed oversight across single or multi-site studies.

    This section outlines the structure, features, and functional capabilities of the dashboard, along with best practices for its effective use in pre-screening and operational management.

    Who Can Access the Dashboard

    Access is role-based to ensure data protection and regulatory compliance. The following users may view and interact with the dashboard:

    • Sponsor Administrators
       (Full visibility across all assigned studies and sites)
    • CRO Administrators
       (Access tied to delegated studies or therapeutic areas)
    • Project Managers & Clinical Operations Leads
       (View-limited or task-specific permissions, as configured)
    • Compliance Monitors
       (Access to audit trails and data verification panels only)

    Each dashboard is encrypted and includes detailed access logs per HIPAA and FDA 21 CFR Part 11 guidelines.

    Core Components of the Dashboard

    1. Trial-Level Overview

    • Number of active, paused, and closed studies
    • Pre-screening status per study
    • IRB document status (uploaded/pending/expired)
    • Study start and projected end dates

    2. Participant Activity

    • Total participants matched
    • Completed pre-screeners
    • Referral conversion rates
    • Participant dropout flags
    • Matching velocity trends (by week/month)

    3. Site Performance Metrics

    • Site-level enrollment activity
    • Time-to-referral averages
    • Screening-to-referral ratio
    • Site-specific protocol deviation flags (if integrated)

    4. Document & Compliance Tracker

    • Upload logs with version control
    • IRB and consent document timestamps
    • Participant-facing communication approvals
    • Consent tracking (pre-screen stage only)

    5. Risk & Oversight Panels

    • Outlier detection in participant matching patterns
    • Flags for rapid dropout or unusual match rates
    • Automatic compliance alerts for missing documentation
    • Task tracker for pending reviews or site queries

    Using the Dashboard for Decision-Making

    Sponsors and CROs can use the dashboard to:

    • Identify underperforming sites in real time
    • Monitor trial outreach and recruitment trends
    • Confirm whether eligibility criteria are too narrow or broad
    • Detect compliance issues early in the participant journey
    • Share operational summaries with internal teams or external stakeholders

    The dashboard supports CSV and PDF exports for regulatory reporting and internal audits.

    Customization & Filters

    The dashboard can be filtered by:

    • Trial phase
    • Study region
    • Site location
    • Participant demographics (if de-identified)
    • Time range (last 7 days, 30 days, custom)

    Admins may also create custom views or save report templates.

    Key Note: Your dashboard is not just a reporting tool, it is a real-time, audit-ready reflection of your trial’s operational health. Use it to proactively identify delays, improve outreach, strengthen site engagement, and stay aligned with regulatory timelines. All actions and reports generated through the dashboard are stored with full traceability to support inspections, interim analyses, and end-of-study reconciliations.

  • Uploading Multi-Site Trials

    The DecenTrialz platform is designed to support both single-site and multi-site clinical trials. Sponsors and CROs managing multi-center studies can upload trials centrally while assigning relevant roles and permissions to each participating research site. This functionality ensures consistency across study protocols, eligibility criteria, and compliance standards, while allowing site-level operational flexibility.

    This section explains the process, permissions, and best practices for uploading and configuring multi-site clinical trials on the platform.

    Who Can Upload Multi-Site Trials

    The following user roles may initiate and manage the upload of a multi-site trial:

    • Sponsor Administrator (Primary responsibility for initiating trials)
    • CRO Administrator (If granted trial setup privileges by the Sponsor)
    • Authorized Delegates (e.g., project leads or data managers with restricted access)

    All trial uploads are logged in the digital audit trail and may be reviewed for compliance purposes.

    Steps to Upload a Multi-Site Trial

    Step 1: Navigate to “Trial Management”

    • Access the Sponsor Dashboard or CRO Dashboard
    • Click on “Add New Trial”
    • Choose the “Multi-Site Trial” option

    Step 2: Complete Trial Overview Form

    Provide core trial metadata including:

    • Study Title and Protocol Number
    • Therapeutic Area and Indication
    • Phase of Study (I, II, III, IV, or observational)
    • Study Start and Expected Completion Dates
    • Primary and Secondary Objectives
    • Sponsor and CRO (if applicable)

    This ensures standardization across all participating sites.

    Step 3: Upload Required Study Documents

    Attach the following:

    • Finalized protocol (PDF)
    • IRB approval letter (if centralized)
    • Investigator Brochure (optional)
    • Site training materials (if available)

    Each document will be available only to the assigned sites and DecenTrialz admins for quality assurance.

    Step 4: Assign Sites to the Trial

    Refer to the Assigning Sites section. You must assign at least one approved site for the trial to move to “Live” status.

    Step 5: Configure Participant Pre-Screening Rules

    • Define global eligibility criteria to apply across all sites
    • Set custom parameters if some sites have local inclusion/exclusion modifications (optional and subject to sponsor sign-off)
    • Select whether participant matching should be handled centrally or by site coordinators

    Step 6: Save as Draft or Submit for Activation

    • Trials can remain in Draft status for internal review
    • Once finalized, mark as “Ready for Review”
    • DecenTrialz Support team will conduct a quality control check before moving the trial to Live

    Best Practices for Multi-Site Uploads

    • Centralize documentation: Ensure all shared materials (protocols, consents, training guides) are consistent across sites.
    • Maintain traceability: Use the audit trail to track all document uploads, modifications, and site assignments.
    • Enable version control: When updating study materials, clearly label version numbers and dates to avoid confusion at the site level.
    • Clarify sponsor-CRO roles: Clearly define who is responsible for document updates, site communication, and compliance tracking.

    Post-Upload Trial Statuses

    • Draft – Not visible to sites, still under internal setup
    • Pending Review – Submitted for DecenTrialz quality review
    • Live – Trial is active and pre-screening can begin
    • Paused – Trial activity temporarily halted (e.g., protocol amendment in progress)
    • Closed – No longer accepting participants

    All status changes are logged and timestamped.

    Key Note: Uploading a multi-site trial through DecenTrialz simplifies operational complexity while maintaining regulatory oversight. By centralizing study setup and standardizing access controls, Sponsors and CROs can ensure that every site runs from the same validated foundation, minimizing risks, reducing errors, and accelerating enrollment readiness.

  • Data Retention Standards

    Data retention is a critical aspect of regulatory compliance, ethical accountability, and operational continuity in clinical research. Research sites using DecenTrialz must ensure that all data collected, generated, and stored during the course of trial recruitment and pre-screening is retained in accordance with applicable laws, institutional policies, and sponsor agreements.

    This section outlines the default data retention policies on the DecenTrialz platform, site-level responsibilities, and key considerations under HIPAA.

    What Is Data Retention in the Context of Clinical Trials?

    Data retention refers to the duration for which clinical trial-related data, including participant screening records, communication logs, audit trails, and regulatory documentation, is securely stored and made accessible for verification, monitoring, or inspection.

    Even though DecenTrialz only handles pre-screening and referral activities, records generated during this phase are subject to the same ethical and regulatory scrutiny as those generated during the full study lifecycle.

    Platform-Level Data Retention Policies (DecenTrialz)

    By default, DecenTrialz maintains a minimum data retention period of 6 years, consistent with HIPAA regulations.

    Data stored includes:

    • Pre-screener responses
    • Eligibility outcomes (without PHI unless consented)
    • Communication records with participants
    • Audit logs of site activity
    • Referral timestamps and status history
    • Site user access records

    All retained data is:

    • Encrypted at rest and in transit
    • Time-stamped and version-controlled
    • Hosted on secure U.S.-based servers compliant with HIPAA and 21 CFR Part 11

    No participant-identifiable data is retained beyond the referral stage unless explicitly consented and governed by the research site’s own data handling protocol.

    Site-Level Responsibilities for Retention

    Although DecenTrialz enforces foundational data retention standards, research sites are ultimately responsible for aligning retention practices with:

    • Local IRB or EC (Ethics Committee) policies
    • Institutional SOPs
    • Sponsor contracts
    • National data protection laws (e.g., HIPAA in the United States, GDPR if operating cross-border)

    You must ensure that:

    • Required study logs and reports are downloaded and archived before trial closure
    • PI (Principal Investigator) oversight is maintained for long-term document custody
    • Participant communication notes and eligibility status history are preserved in case of audits

    Sites may export DecenTrialz-generated data to their internal systems using the “Download Record Archive” feature prior to trial archival.

    Retention of Consent-Related Records

    Even during the pre-screening stage, some communications (such as expressions of interest or voluntary opt-ins) may constitute limited informed consent records. These must also be retained for a minimum of 6 years, or longer if your IRB or sponsor requires.

    If your site collects any additional documentation from participants outside of the DecenTrialz system (e.g., handwritten notes, phone transcripts), retention of those records must also follow institutional policy.

    Data Destruction After Retention Period

    At the end of the applicable retention period:

    • DecenTrialz will notify site administrators prior to scheduled data archiving or destruction
    • Sites may request extended retention or secure export for permanent archiving

    Sites must not delete any data prematurely without written authorization from the sponsor and/or IRB.

    Key Note: Maintaining accurate, secure, and complete data records is an ethical obligation and a legal requirement. Failure to retain data for the appropriate duration can lead to regulatory penalties, audit deficiencies, or even trial invalidation. Always confirm your site’s retention policy with your IRB or institution’s research office and document all retention-related decisions for audit readiness.

  • Reporting to Sponsors

    Timely and transparent communication with study sponsors is a critical responsibility for all research sites. The DecenTrialz platform is equipped with features that support standardized, audit-ready reporting to sponsors at every phase of participant engagement and study operations,  particularly during the pre-screening and referral process.

    This section outlines what information can be shared with sponsors, how to generate reports from the platform, and the ethical and regulatory considerations for site-to-sponsor communication.

    What Can Be Reported to Sponsors via DecenTrialz?

    Sponsors may require regular updates from sites to track recruitment progress, assess protocol adherence, and ensure overall study performance. The DecenTrialz platform enables sites to report pre-screening-level data that is:

    • De-identified (unless explicit participant consent allows otherwise)
    • Aggregated or participant-level, depending on sponsor needs and IRB allowances
    • Fully aligned with ICH-GCP, HIPAA, and 21 CFR Part 11 requirements

    Typical reporting categories include:

    Report TypeDetails Shared
    Prescreening Funnel MetricsNumber of pre-screeners started, completed, disqualified
    Referral ActivityNumber of participants referred, referral timestamps
    Eligibility TrendsCommon inclusion/exclusion barriers (non-identifiable)
    Participant DispositionInterested, declined, unreachable, withdrawn (no PHI shared)
    Communication LogsContact attempt dates, no content of messages shared

    Important: Sites must never share identifiable health data or direct participant contact details with sponsors unless:

    • Explicit consent has been obtained
    • Sharing is IRB-approved
    • Required by a regulatory agreement and properly documented

    How to Generate Reports for Sponsors

    Site admins and delegated coordinators can generate sponsor-ready reports directly from the Reporting Module on DecenTrialz.

    To Create a Sponsor Report:

    1. Navigate to Dashboard → Reporting → Sponsor Reports
    2. Select your trial of interest
    3. Choose reporting period (e.g., weekly, monthly, custom)
    4. Select metrics to include:
      • Referral stats
      • Pre-screener conversion
      • Communication status
      • IRB document updates (if applicable)
    5. Click Generate Report
    6. Download in PDF or CSV format, or securely share via sponsor-facing portal link (if activated)

    All reports are automatically:

    • Timestamped and version-controlled
    • Watermarked with trial ID and your site code
    • Backed by corresponding audit logs (see Section 5.3.1)

    Sponsor Portal Access (Optional)

    If enabled by the sponsor and permitted by the site, certain designated sponsor representatives may receive read-only access to a real-time recruitment dashboard.

    Sponsor views are:

    • Permission-controlled
    • Anonymized by default
    • Monitored by the platform to prevent data misuse

    You may control what metrics are shared and revoke access at any time via the Site Admin Panel.

    Regulatory and Ethical Responsibilities

    When reporting to sponsors, your site must adhere to the following standards:

    • Do not overstate or understate enrollment progress
    • Avoid sending reports via unsecured or personal email
    • Ensure internal consistency between platform data and your own site SOP logs
    • Include IRB reference numbers when submitting updates on approved protocol changes

    Sponsors rely on site-reported data to make trial-wide decisions, including budget adjustments, site activation status, and recruitment strategy shifts. Accuracy and ethical rigor are essential.

    Key Note: All sponsor reports generated through DecenTrialz are designed to protect participant confidentiality while ensuring full transparency around recruitment and referral activity. When in doubt, always confirm with your site PI or IRB liaison before sharing sensitive or detailed metrics.

  • Logging Consent Progress (Pre-Screening Stage Only)

    In the DecenTrialz platform, participant consent is a multi-step process, beginning with digital pre-screening and concluding at the research site after full consent and enrollment procedures. As a research site, your responsibility during the pre-screening stage is to accurately log whether a participant has been:

    • Contacted with IRB-approved information
    • Provided initial details about the study
    • Given the opportunity to ask questions
    • Informed that no decisions or commitments are required at this stage

    This section outlines how to log consent-related progress ethically and accurately, while remaining fully aligned with U.S. regulations such as 21 CFR Part 50, ICH-GCP, and HIPAA.

    What Is Considered ‘Consent Progress’ at the Pre-Screening Stage?

    While formal informed consent (signing a full consent form) does not occur until the participant visits or engages with the research site directly, there are important ethical touchpoints that must still be documented.

    At the pre-screening stage, consent progress may include:

    • Participant has been contacted and acknowledged your outreach
    • Participant has received basic study information
    • Participant expressed continued interest or requested more information
    • Participant verbally agreed to proceed to site-level consent

    This process ensures that participants are never enrolled or pressured prematurely and are aware of their rights, including the right to delay or decline.

    How to Log Consent Progress in DecenTrialz

    To maintain an accurate and auditable record, site teams must use the DecenTrialz platform to log each step taken:

    1. Access the Match Dashboard
      • Locate the participant under your active matches list.
    2. Open the Consent Progress Panel
      • Select the participant and click on “Log Progress.”
    3. Choose the Appropriate Status
      • Contact Attempted – No Response
      • Initial Info Shared – Awaiting Feedback
      • Participant Requested More Info
      • Verbal Interest Confirmed – Ready for Site Consent
      • Participant Declined
    4. Add Optional Notes
      • (e.g., “Called on July 2, participant asked for study brochure.”)
    5. Save and Timestamp
      • The entry will be locked and added to the audit trail.

    Important: This log is not a legal substitute for signed informed consent. It exists solely to document pre-screening communication and participant status as part of early engagement tracking.

    Why This Step Is Important

    Logging consent progress:

    • Ensures transparency and consistency across your site team
    • Helps monitor participant interest and readiness
    • Supports regulatory documentation during audits
    • Protects both the participant and the site from miscommunication
    • Enables smoother handoffs between coordinators and investigators

    Even if a participant decides not to proceed, logging this accurately helps the platform avoid duplicate follow-ups or unnecessary recontact.

    Consent-Related Language to Use During Pre-Screening

    To avoid coercion and ensure clarity, use approved phrasing when discussing next steps. For example:

    Acceptable:

    • “Would you like to receive more information about this study?”
    • “You’re welcome to take time before making any decisions.”
    • “If you’re still interested, we can set up a time for you to speak with our site team.”

    Avoid:

    • “You’ve been selected for the study.”
    • “We can enroll you today.”
    • “This is your only chance to join.”

    All communications must reflect voluntariness and allow for participant autonomy.

    Exporting Consent Logs for Auditing

    Site admins may export consent logs as part of the study documentation package. Export files include:

    • Participant ID (de-identified)
    • Date/time of status changes
    • Action taken and by whom
    • Notes (if any)

    These logs may be used for:

    • IRB reporting
    • Sponsor communication
    • Site SOP audits


    Key Note: Logging consent progress at the pre-screening stage is not just a recordkeeping task, it is an ethical safeguard. It ensures that each participant is approached respectfully, kept informed, and never advanced without their awareness or agreement. Always prioritize clarity, voluntariness, and proper documentation.

  • Communication Etiquette

    Effective and respectful communication with matched participants is a critical component of ethical clinical research. As soon as your site chooses to accept a participant through the DecenTrialz platform, all subsequent interactions whether via phone, email, SMS, or another approved method, must align with institutional review board (IRB) guidelines, participant rights, and industry regulations.

    This section outlines the principles and expectations for site-to-participant communication during the pre-screening and referral process.

    Why Communication Matters

    Each participant matched to your site is a prospective volunteer who has:

    • Taken the time to complete a health-based pre-screener
    • Expressed interest in learning more about clinical research
    • Not yet committed to enrollment or in-person screening

    The goal of your communication is not to convince or enroll, but to inform, answer questions, and support the participant’s decision-making process. This includes helping them understand what to expect and whether the study may be right for them, without pressure or bias.

    Core Communication Principles

    When contacting a matched participant, site staff must follow these principles:

    PrincipleDescription
    Respect & DignitySpeak with empathy. Acknowledge their time, interest, and right to ask questions or decline.
    Clarity & SimplicityUse plain, accessible language. Avoid complex medical terms unless the participant asks.
    TransparencyClearly state your name, role, the trial name, and why you are contacting them.
    VoluntarinessEmphasize that participation is voluntary and that they may opt out at any time.
    No PressureNever use urgency, guilt, or incentives to pressure participation or scheduling.
    Privacy RespectConfirm the participant’s identity discreetly before discussing study details.

    Before You Initiate Contact

    Before making contact, site teams must:

    • Confirm the participant has been formally accepted in the Match Dashboard
    • Review their pre-screener responses to tailor your outreach appropriately
    • Use only the IRB-approved contact script or templates stored in your site’s communication library
    • Determine the best time and method for outreach based on participant-provided preferences (when available)

    Reminder: Participants may withdraw their interest at any time. If a participant communicates withdrawal, mark the record accordingly and cease further contact.

    What to Say in the First Message or Call

    Your initial outreach should include the following elements:

    1. Your name and institutional affiliation
       (e.g., “Hello, my name is Dr. Patel, and I’m a research coordinator at ABC Medical Center.”)
    2. Mention of DecenTrialz referral
       (e.g., “You recently filled out a brief survey on DecenTrialz, and based on your answers, we’d like to share more about a study we’re conducting.”)
    3. Clarification of next steps
       (e.g., “This call is just to provide information. You can take your time before deciding whether to move forward.”)
    4. Respect for time and consent to proceed
       (e.g., “Is this a good time to speak, or would you prefer to schedule a follow-up?”)

    Recording Calls

    Some jurisdictions require participants to be notified if a call is being recorded. If your site records outreach for training or compliance, always obtain verbal consent (e.g., “With your permission, this call may be recorded for quality purposes.”)

    Do’s and Don’ts of Participant Communication

    Do:

    • Use professional, polite language
    • Let the participant lead the pace of the conversation
    • Provide IRB-approved study facts
    • Log each contact attempt and response in the platform

    Don’t:

    • Promise benefits or outcomes
    • Misrepresent the nature of the study
    • Use phrases like “you have been selected” (unless IRB-approved)
    • Discuss non-study-related health advice

    Handling Sensitive Scenarios

    If a participant:

    • Expresses fear or uncertainty: Acknowledge their concerns and offer to provide official materials or follow-up later.
    • Requests a copy of the consent form early: Refer them to the site’s standard process or send pre-consent material, if approved.
    • Mentions previous negative trial experiences: Remain empathetic and non-defensive. Offer support without persuasion.

    All team members must complete DecenTrialz communication compliance training before outreach begins.

    Inclusivity Note: If a participant appears to require additional language support or accessibility accommodations, refer to your institution’s translation and communication assistance policies. DecenTrialz also offers template guidance in multiple languages upon request.

    Documenting Your Outreach

    Every communication attempt must be logged in the system with:

    • Date and time
    • Type (call, email, SMS, etc.)
    • Outcome (spoke, no answer, follow-up needed)
    • Notes (optional but recommended for continuity)

    This log supports audit readiness and protects participant safety and site integrity.

    Key Note: Communication with participants is not just outreach, it is a reflection of your site’s professionalism, ethical standards, and commitment to human research protection. Treat every interaction with care, transparency, and respect. Always defer to IRB guidance when in doubt, and never substitute informal practices for approved protocol.